All medicinal products authorised in the EU must include specific labelling and product‑information elements. According to the requirements under European Medicines Agency (EMA) and the EU pharmaceutical legislation (Directive 2001/83/EC and related regulations), packaging and package leaflets must contain, among other things: the product name, strength and pharmaceutical form, active ingredients, route of administration, expiry date and batch number, storage conditions, manufacturer details, and safety or storage warnings if applicable.

The package leaflet (for patients) – and the Summary of Product Characteristics (SmPC, for healthcare professionals) – must reflect up‑to‑date product information and meet readability and content standards defined by EMA.

Labelling updates or variations may be required for multiple reasons post‑approval: safety updates (e.g., new adverse reactions), change of storage or handling conditions, change in packaging materials or artwork, updates in excipient information (e.g., due to new regulations about allergens or excipient disclosure), updates in product strength or dosage form, or regulatory-driven format changes (e.g., updates to leaflet readability or language requirements).

Such changes must follow procedures defined by EMA’s lifecycle and variation guidelines. For centrally authorised products, updates to labelling or package leaflet should use the current Quality Review of Documents (QRD) template maintained by EMA.

While the general labelling/packaging rules apply to all medicines, for Advanced Therapy Medicinal Products (ATMPs) and other special medicines there are additional specific requirements. This may include explicit description of the nature of the product (e.g., cell/tissue origin), handling/storage conditions specific to biologics or cell‑based therapies, and clear patient instructions to ensure safe use.

Packaging and labelling for such products must reflect their particularities to ensure safety, traceability, and compliance with regulatory expectations.

Regulatory labelling services must adhere to a set of official documents and guidelines, including:

• EMA’s “Product information requirements” guidance for human medicines.
• The QRD template: the standard format for Summary of Product Characteristics (SmPC), patient leaflets, and labelling for centrally authorised medicines.
• Guidelines on packaging and labelling for medicinal products and specific requirements for readability, patient information and safety features (e.g., storage conditions, expiry date, batch number, all required fields per Directive 2001/83/EC)
• For special categories such as ATMPs — additional packaging/labelling rules covering cell/tissue‑based products

Using these as reference ensures that labelling services meet regulatory compliance and reduce risk of non-conformities.

A specialised labelling service or regulatory consultancy can support the full lifecycle of labelling and packaging compliance, including:

• Drafting and updating SmPCs, package leaflets, and labels according to the latest QRD templates and regulatory requirements.
• Managing multi‑language packaging and leaflets for different EU markets.
• Handling labelling updates triggered by safety changes, packaging changes, excipient changes, or regulatory updates.
• Ensuring compliance with readability, translation, local requirements, and artwork regulations (batch, expiry, storage, safety statements).
• Coordinating with packaging, artwork, printing, and supply chain stakeholders to ensure correct implementation and avoid delays.

Given the complexity of EU requirements – especially for biologics, ATMPs, or multi-market distribution – outsourcing labelling operations often saves time, reduces risk, and ensures compliance across markets.